



RATIONAL Platform Trial
RATIONALISE Trial


Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy

Newsletter December 2024

Welcome to the December newsletter for the RATIONAL platform trial and RATIONALISE trial (the STOP-Ig domain of the RATIONAL platform).

Lower rates of infection in summer?

Victorian data 2007-2021 (provided courtesy of Rainier Arnolda, VALUE-Ig study) shows that the highest rates of infection-related hospitalisations for myeloma patients occur in September. Lower rates of hospitalisation in summer mean that now is an ideal time to consider which patients might be eligible to join the RATIONALISE trial (STOP-Ig domain).



Presentations at Blood 2024 and ALLG scientific meeting

Prof Zoe McQuilten provided an overview of the unanswered questions in immunoglobulin therapy at the Blood 2024 conference in Brisbane, and followed with an outline of the RATIONAL platform trial at the ALLG scientific meeting in Melbourne.



Team update

We're sad to announce that Dr Nicole Eise left the RATIONALISE and RATIONAL team in November to take up a new opportunity. We thank Nicole for all her efforts as part of our team, and wish her the very best in her new role.

Our team are still working hard on the trial, and we'll keep you updated on any further changes in the new year. In the meantime, please continue to send any communication about both RATIONALISE and RATIONAL-PT to sphpm.rationalise@monash.edu

Please note that we will take a short break from Dec 21st to Jan 2nd, and wish everyone a very happy holiday season!



RATIONAL Platform Trial
RATIONALISE Trial

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy

Contact us at:
sphpm.rationalise@monash.edu